双打击淋巴瘤强化一线免疫化疗失败后治愈性二线治疗结局不佳
该结局可作为未来二线治疗策略的参照标准。
要点
- 双打击淋巴瘤强化一线失败后二线免疫化疗缓解率低,中位PFS仅2个月。
- 二线治疗后1年PFS和OS分别为10%和19%,提示亟需非细胞毒性新策略。
- 该队列结局可作为复发/难治双打击淋巴瘤二线治疗研究的基准。
核心结论
- 双打击淋巴瘤患者强化一线免疫化疗失败后,接受治愈性二线免疫化疗的结局很差。
研究设计与样本
- 研究识别了55例强化一线免疫化疗失败后接受治愈性二线免疫化疗的双打击淋巴瘤患者。
主要发现
- 二线治疗后总缓解率为29%,完全缓解率为11%。
- 二线治疗后1年无进展生存率为10%,1年总生存率为19%。
临床怎么用
- 该结局可作为未来复发/难治双打击淋巴瘤二线治疗策略的疗效参照标准。
- 结果支持在二线治疗中探索非细胞毒性疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While patients with double-hit lymphoma (DHL) are now frequently treated with intensive front-line immunochemotherapy, outcomes for those who fail these regimens and subsequently receive curative-intent second-line immunochemotherapy are unknown. We identified 55 such patients who achieved an overall/complete response rate of 29%/11%, median progression-free/overall survival (PFS/OS) of 2/5·1 months and one-year PFS/OS of 10/19% following the start of second-line therapy. These outcomes may serve as a standard against which future second-line treatment strategies for relapsed/refractory DHL can be measured and justify investigation of non-cytotoxic therapies in the second-line setting for these patients.
引用
- Landsburg DJ, Ayers EC, Bond DA, et al. Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. Br J Haematol. 2019. PMID: 31804715. doi:10.1111/bjh.16319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。